BackVentana Biotech Overview
Ventana Biotech, Inc.

Ventana Biotech Return on Equity

Valuation check: VNTA's ROE is -97.55%, below the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

-97.55%

Return on Equity

-97.55%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Ventana Biotech (VNTA) FAQ

The latest ROE for VNTA is -97.55%. That is below the sector sector average of 11.3%. Investors often review this figure alongside Ventana Biotech's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, VNTA currently prints -97.55% for ROE, while the sector average sits near 11.3%. That is roughly 963.6% below the sector mean. Large gaps often invite a closer look at Ventana Biotech's growth, margins, and balance sheet.

Return on Equity shows how effectively Ventana Biotech converts resources into returns. At -97.55%, VNTA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VNTA's ROE (-97.55%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.